CULLINAN THERAPEUTICS, INC. Operating Income
CULLINAN THERAPEUTICS, INC. (CGEM) reported Operating Income of -$57.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-06-30 was -$57.25M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2026-03-31 was -$53.70M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-12-31 was -$55.26M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for the quarter ending 2025-09-30 was -$55.59M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for fiscal 2025 was -$241.65M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for fiscal 2024 was -$196.92M.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for fiscal 2023 was -$191.09M, a 232.11% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. operating income (loss) for fiscal 2022 was $144.65M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$57.25M 10-Q · filed 2026-08-06 | -$110.95M 10-Q · filed 2026-08-06 | -$166.21M derived: sum of 3 quarters · filed 2026-08-06 | -$221.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$53.70M 10-Q · filed 2026-05-07 | -$108.96M derived: sum of 2 quarters · filed 2026-05-07 | -$164.55M derived: sum of 3 quarters · filed 2026-05-07 | -$240.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$55.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$110.85M derived: sum of 2 quarters · filed 2026-03-10 | -$186.65M derived: sum of 3 quarters · filed 2026-08-06 | -$241.65M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$55.59M 10-Q · filed 2025-11-06 | -$131.39M derived: sum of 2 quarters · filed 2026-08-06 | -$186.39M 10-Q · filed 2025-11-06 | -$241.44M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$75.80M 10-Q · filed 2026-08-06 | -$130.79M 10-Q · filed 2026-08-06 | -$185.84M derived: sum of 3 quarters · filed 2026-08-06 | -$234.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$55.00M 10-Q · filed 2026-05-07 | -$110.04M derived: sum of 2 quarters · filed 2026-05-07 | -$158.90M derived: sum of 3 quarters · filed 2026-05-07 | -$208.93M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$55.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$103.90M derived: sum of 2 quarters · filed 2026-03-10 | -$153.93M derived: sum of 3 quarters · filed 2026-03-10 | -$196.92M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$48.85M 10-Q · filed 2025-11-06 | -$98.88M derived: sum of 2 quarters · filed 2025-11-06 | -$141.87M 10-Q · filed 2025-11-06 | -$187.36M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$50.03M 10-Q · filed 2025-08-07 | -$93.02M 10-Q · filed 2025-08-07 | -$138.50M derived: sum of 3 quarters · filed 2025-08-07 | -$183.74M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$42.99M 10-Q · filed 2025-05-08 | -$88.47M derived: sum of 2 quarters · filed 2025-05-08 | -$133.72M derived: sum of 3 quarters · filed 2025-05-08 | -$171.32M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$45.48M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$90.73M derived: sum of 2 quarters · filed 2025-02-27 | -$128.33M derived: sum of 3 quarters · filed 2025-02-27 | -$191.09M 10-K · filed 2025-02-27 |
| 2023-09-30 | -$45.24M 10-Q · filed 2024-11-07 | -$82.85M derived: sum of 2 quarters · filed 2024-11-07 | -$145.60M 10-Q · filed 2024-11-07 | -$178.21M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$37.60M 10-Q · filed 2024-08-08 | -$100.36M 10-Q · filed 2024-08-08 | -$132.97M derived: sum of 3 quarters · filed 2024-08-08 | -$162.74M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$62.76M 10-Q · filed 2024-05-15 | -$95.36M derived: sum of 2 quarters · filed 2024-05-15 | -$125.13M derived: sum of 3 quarters · filed 2024-05-15 | $114.55M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$32.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$62.37M derived: sum of 2 quarters · filed 2024-03-14 | $177.31M derived: sum of 3 quarters · filed 2024-03-14 | $144.65M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$29.77M 10-Q · filed 2023-11-08 | $209.91M derived: sum of 2 quarters · filed 2023-11-08 | $177.26M 10-Q · filed 2023-11-08 | $142.91M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $239.68M 10-Q · filed 2023-08-10 | $207.02M 10-Q · filed 2023-08-10 | $172.68M derived: sum of 3 quarters · filed 2023-08-10 | $154.30M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$32.66M 10-Q · filed 2023-05-11 | -$67.00M derived: sum of 2 quarters · filed 2023-05-11 | -$85.38M derived: sum of 3 quarters · filed 2023-05-11 | -$101.98M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$34.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$52.72M derived: sum of 2 quarters · filed 2023-03-09 | -$69.33M derived: sum of 3 quarters · filed 2023-03-09 | -$67.95M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$18.38M 10-Q · filed 2022-11-14 | -$34.98M derived: sum of 2 quarters · filed 2022-11-14 | -$33.61M 10-Q · filed 2022-11-14 | -$62.78M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$16.60M 10-Q · filed 2022-08-10 | -$15.23M 10-Q · filed 2022-08-10 | -$44.41M derived: sum of 3 quarters · filed 2022-08-10 | -$55.90M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $1.37M 10-Q · filed 2022-05-16 | -$27.80M derived: sum of 2 quarters · filed 2022-05-16 | -$39.30M derived: sum of 3 quarters · filed 2022-05-16 | -$53.42M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$29.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$40.67M derived: sum of 2 quarters · filed 2022-03-17 | -$54.79M derived: sum of 3 quarters · filed 2022-03-17 | -$60.34M 10-K · filed 2022-03-17 |
| 2020-09-30 | -$11.50M 10-Q · filed 2021-11-09 | -$25.62M derived: sum of 2 quarters · filed 2021-11-09 | -$31.16M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | -$14.12M 10-Q · filed 2021-08-10 | -$19.66M 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$5.54M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |